Tamekia Scaggs
Psychiatric/Mental Health · Fort Worth, TXNPI 1912476268
Payments from drug & device makers
Across 749 payments — averaging $106.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$64K
- E.r. Squibb & Sons, L.L.C.$4K
- Neurocrine Biosciences, Inc.$2K
- Johnson & Johnson$2K
- Alkermes, Inc.$2K
- AbbVie$1K
- plus $5K from 12 others
What the payments were for
- Speaking & faculty fees$54,04568%
- Travel & lodging$8,11210%
- Food & beverage$17,30422%
- Education$1320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 210 | $63,610 |
| E.r. Squibb & Sons, L.L.C. | 45 | $4,319 |
| Neurocrine Biosciences, Inc. | 80 | $2,425 |
| Johnson & Johnson | 74 | $1,891 |
| Alkermes, Inc. | 46 | $1,532 |
| AbbVie | 73 | $1,224 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 65 | $1,138 |
| Vanda Pharmaceuticals Inc. | 33 | $792 |
| Indivior Inc. | 32 | $558 |
| Otsuka America Pharmaceutical, Inc. | 25 | $466 |
| Sunovion Pharmaceuticals Inc. | 27 | $376 |
| Lundbeck LLC | 26 | $370 |
| Luye Pharma (USA) Ltd. | 7 | $341 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $174 |
| Esperion Therapeutics, Inc. | 1 | $125 |
| Novo Nordisk | 1 | $119 |
| Axsome Therapeutics, Inc. | 1 | $117 |
| Organon | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UZEDY$59,811
- COBENFY$3,308
- LYBALVI$1,347
- INGREZZA$635
- INVEGA SUSTENNA$373
- INVEGA TRINZA$354
- VRAYLAR$327
- ERZOFRI EXTENDED-RELEASE$248
- CAPLYTA$227
- NEXLIZET$125
- NEXLETOL$125
- REXULTI$125
- AUSTEDO$122
- Austedo XR$121
- Wegovy$119
- Auvelity$117
- Fanapt$116
How this compares
$79,593 in reported general payments places this provider in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 55 | $420,591 |
| Invega SustennaPaliperidone Palmitate | 27 | $81,416 |
| UzedyRisperidone | 11 | $65,170 |
| FanaptIloperidone | 12 | $48,375 |
| VraylarCariprazine Hcl | 13 | $21,371 |
| Oxcarbazepine | 44 | $2,951 |
| Aripiprazole | 46 | $2,269 |
| Quetiapine Fumarate | 67 | $1,851 |
| Buspirone Hcl | 120 | $1,487 |
| Citalopram HbrCitalopram Hydrobromide | 28 | $1,286 |
| Duloxetine Hcl | 38 | $1,133 |
| Trazodone Hcl | 127 | $977 |
| Divalproex Sodium ErDivalproex Sodium | 20 | $969 |
| Bupropion XlBupropion Hcl | 26 | $967 |
| Ziprasidone Hcl | 22 | $933 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Uzedy | $63,610 | $485,76166 claims |
| Johnson & JohnsonInvega Sustenna | $1,891 | $81,41627 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $792 | $48,37512 claims |
| AbbVieVraylar | $1,224 | $21,37113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.
Other psychiatric/mental health in Fort Worth
- Tracy HicksLongview$684K
- Natalie TellezHouston$602K
- Karah BrashierRichardson$567K
- Grant DavisRichardson$360K
- Victor IlogEl Paso$167K
- Lisa ShamblinGrapevine$163K
- Monique GonzalezSan Antonio$126K
- Marguerite AddisonWaco$118K
- Komi Kokou-AbiRound Rock$88K
- Jaime Nelson DensonAustin$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.